In agreement with these findings, Ahmadzadehfar et al. have shown a negative impact of bone metastasis on the survival of patients treated with PSMA-RLT in 11 different clinics in a multicenter study, including data from more than 400 mCRPC patients [22]. This evidence concerns the gene FOLH1 and bone metastasis.